semaglutide may 2025 As of February 21, 2025, the FDA updated its drug shortage list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A Tirzepatide vs Semaglutide: 2025 NEJM

Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved

Journal of Virology

Presented for research literature review only Moslemi Mehni N et al

Members with obesity, metabolic syndrome, type 2 diabetes, or anyone struggling with weight loss who hasnt had success with lifestyle alone

Semaglutide is one of several glucagon-like peptide-1 (GLP-1) receptor agonists, along with liraglutide (brand names Saxenda , Victoza ), dulaglutide (brand name Trulicity ), and others